CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

Otros idiomas Creative Medical Technology Holdings, Inc.

Acciones

CELZ

US22529Y4089

Diferido Nasdaq Otros sitios de cotización 21:39:55 13/05/2024			Varia. Cinco días.	Varia. 1 de enero.
4,44 ^USD	+2,07 %		-0,45 %	-3,69 %

10/05	Creative Medical Technology Holdings, Inc. informa de los resultados del primer trimestre finalizado el 31 de marzo de 2024	CI
22/03	Creative Medical Technology Holdings, Inc. informa de los resultados del ejercicio finalizado el 31 de diciembre de 2023	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Creative Medical Technology Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05
Creative Medical Technology Holdings Provides Corporate Update	27/03
Tranche Update on Creative Medical Technology Holdings, Inc.'s Equity Buyback Plan announced on June 12, 2023.	22/03
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03
Creative Medical Shares Rise 37% After FDA Authorization for CELZ-201	07/03
Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access	07/03
Creative Medical Technology Holdings Inc. Announces FDA Authorization for Type 1 Diabetes Prevention Therapy Under Expanded Access	07/03
Creative Medical Technology Holdings Gets US FDA Orphan Drug Designation; Shares Rise	06/03
Private Payrolls Data, Upcoming Powell Testimony Drive Higher Premarket Action for US Equity Futures	06/03
Creative Medical Shares Rally Premarket on FDA Orphan Designation	06/03
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Ahead of Powell Testimony	06/03
Top Premarket Gainers	06/03
Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy	06/03
Creative Medical Technology Holdings, Inc. Receives Clearance from the FDA to Conduct a Phase 1/2 Clinical Trial Using Their Innovative StemSpine Treatment Known as AlloStem	20/12
Creative Medical Technology Holdings Provides Corporate Update	15/11
Tranche Update on Creative Medical Technology Holdings, Inc.'s Equity Buyback Plan announced on June 12, 2023.	14/11
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine using AlloStem Novel Cell Therapy to Treat Chronic Lower Back Pain	11/10/23
Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain	10/10/23
Creative Medical Technology Holdings, Inc. Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Stemspine(R) Using Allostem(Tm) (Celz-201-Ddt) Novel Cell Therapy to Treat Chronic Lower Back Pain	10/10/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Creative Medical Technology Holdings, Inc.

Acciones

CELZ

US22529Y4089

Otros idiomas

Filtros